https://www.bloomedi.com/ko/media/breast/china-expands-liporaxel-approval-to-her2-negative-breast-cancer-194053 MediIndex ko 2026-10-08T14:34:43.152Z 중국, 리포락셀액 HER2 음성 유방암 적응증 추가 승인 https://www.bloomedi.com/en/media/breast/china-expands-liporaxel-approval-to-her2-negative-breast-cancer-194053 MediIndex en 2026-10-08T14:34:43.152Z China Expands Liporaxel Approval to HER2-Negative Breast Cancer https://www.bloomedi.com/ko/media/skin/team-develops-skin-tone-conversion-ai-for-skin-diagnosis-c46f34 MediIndex ko 2026-10-08T04:37:07.890Z 서울아산병원 연구팀, 피부질환 진단용 피부색 변환 AI 개발 https://www.bloomedi.com/en/media/skin/team-develops-skin-tone-conversion-ai-for-skin-diagnosis-c46f34 MediIndex en 2026-10-08T04:37:07.890Z Team Develops Skin-Tone Conversion AI for Skin Diagnosis https://www.bloomedi.com/ko/media/skin/foreign-skin-and-plastic-surgery-visits-rose-82-5-in-korea-750a23 MediIndex ko 2026-10-08T04:36:38.395Z 한국 피부·성형외과 외국인 환자 154만명, 전년보다 82.5% 증가 https://www.bloomedi.com/en/media/skin/foreign-skin-and-plastic-surgery-visits-rose-82-5-in-korea-750a23 MediIndex en 2026-10-08T04:36:38.395Z Foreign Skin and Plastic Surgery Visits Rose 82.5% in Korea https://www.bloomedi.com/ko/media/eye/myopia-risks-persist-after-vision-correction-society-warns-3b7b23 MediIndex ko 2026-10-08T04:35:56.479Z 대한안과학회 “시력교정 후에도 고도근시 위험 남아 평생 관리 필요” https://www.bloomedi.com/en/media/eye/myopia-risks-persist-after-vision-correction-society-warns-3b7b23 MediIndex en 2026-10-08T04:35:56.479Z Myopia Risks Persist After Vision Correction, Society Warns https://www.bloomedi.com/ko/media/eye/court-awards-damages-over-same-day-cataract-surgery-consent-b484ce MediIndex ko 2026-10-08T00:36:45.994Z 백내장 수술 첫 방문 당일 시행, 법원 설명의무 위반 인정 https://www.bloomedi.com/en/media/eye/court-awards-damages-over-same-day-cataract-surgery-consent-b484ce MediIndex en 2026-10-08T00:36:45.994Z Court Awards Damages Over Same-Day Cataract Surgery Consent https://www.bloomedi.com/ko/media/breast/fda-expands-tukysa-to-her2-positive-breast-cancer-maintenance-178898 MediIndex ko 2026-10-08T00:36:13.887Z FDA, 투키사 HER2 양성 진행성 유방암 유지요법 승인 https://www.bloomedi.com/en/media/breast/fda-expands-tukysa-to-her2-positive-breast-cancer-maintenance-178898 MediIndex en 2026-10-08T00:36:13.887Z FDA Expands Tukysa to HER2-Positive Breast Cancer Maintenance https://www.bloomedi.com/ko/media/skin/duotite-registered-as-a-medical-device-in-thailand-7d60d8 MediIndex ko 2026-10-07T02:35:15.773Z 비올메디컬 듀오타이트, 태국 의료기기 등록 완료 https://www.bloomedi.com/en/media/skin/duotite-registered-as-a-medical-device-in-thailand-7d60d8 MediIndex en 2026-10-07T02:35:15.773Z DUOTITE Registered as a Medical Device in Thailand https://www.bloomedi.com/ko/media/skin/merz-names-fencer-oh-sang-uk-as-ultherapy-prime-model-86cc54 MediIndex ko 2026-10-07T02:34:43.963Z 멀츠, 펜싱 국가대표 오상욱 울쎄라피 프라임 모델 발탁 https://www.bloomedi.com/en/media/skin/merz-names-fencer-oh-sang-uk-as-ultherapy-prime-model-86cc54 MediIndex en 2026-10-07T02:34:43.963Z Merz Names Fencer Oh Sang-uk as Ultherapy PRIME Model